Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Articles

A Riddle Wrapped in a Mystery Inside an Enigma: The Biologics Price Competition and Innovation Act has ended up in the U.S. Court of Appeals for the Federal Circuit

September 11, 2015

Articles

A Riddle Wrapped in a Mystery Inside an Enigma: The Biologics Price Competition and Innovation Act has ended up in the U.S. Court of Appeals for the Federal Circuit

September 11, 2015

Back to News Listing

​Principal Dorothy Whelan is quoted in IPPro Life Sciences‘ article "A Riddle Wrapped in a Mystery Inside an Enigma: The Biologics Price Competition and Innovation Act has ended up in the U.S. Court of Appeals for the Federal Circuit."

Whelan commented on the Amgen v. Sandoz July 2015 ruling. "Amgen isn’t exactly worse off—the split judgement also went in its favour. There are a lot of protections built in for the branded company. Irrespective of their patent expiration dates, the statute gives them a number of days of exclusivity. With the 180-day notice issued, Sandoz must wait for regulatory approval, which effectively adds a six-month exclusivity period for Amgen." 

Read the full article here.


The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.